ESR1 and breast carcinoma: The lack of estrogen receptors (ER) has rendered MDA-MB-231 cells insensitive to treatments with antiestrogens, such as tamoxifen [10], which is widely used in breast cancer chemoprevention [11], but also as an adjuvant in treatment of primary disease [12].